PEMAZYRE
Live / Registered — Registered — Section 8 accepted (as of 22 Oct 2025)
What this means for you
Registered since 23 Jun 2020. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 87822632
- Registration number
- 6086147
- Mark type
- Stylized text
- Filed
- 06 Mar 2018
- Published for opposition
- 01 May 2018
- Registered
- 23 Jun 2020
- Attorney of record
- Frances M. Jagla
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of immunological disorders; pharmaceutical preparations for the treatment of hematological disorders; pharmaceutical preparations for the treatment of hypophosphatemia disorders; pharmaceutical preparations for the treatment of myeloproliferative disorders [ ; pharmaceutical preparations for the treatment of skeletal or chondrocyte disorders ]
Owner
- Incyte Holdings Corporation, Wilmington, DE, US
- Incyte Holdings Corporation, Wilmington, DE, US
- Incyte Holdings Corporation, Wilmington, DE, US
Prosecution history
- 22 Oct 2025 — NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED
- 22 Oct 2025 — REGISTERED - SEC. 8 (6-YR) ACCEPTED
- 20 Oct 2025 — CASE ASSIGNED TO POST REGISTRATION PARALEGAL
- 20 Oct 2025 — CASE ASSIGNED TO POST REGISTRATION PARALEGAL
- 26 Jun 2025 — TEAS SECTION 8 RECEIVED
- 23 Jun 2025 — COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
- 23 Jun 2020 — REGISTERED-PRINCIPAL REGISTER
- 21 May 2020 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 20 May 2020 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 19 May 2020 — STATEMENT OF USE PROCESSING COMPLETE
- 01 May 2020 — USE AMENDMENT FILED
- 18 May 2020 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 01 May 2020 — TEAS STATEMENT OF USE RECEIVED
- 11 Apr 2020 — APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
- 11 Apr 2020 — TEAS CHANGE OF CORRESPONDENCE RECEIVED